Crescent Biopharma, Inc.
CBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $15 | $16 | $7 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $15 | $16 | $7 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -86.7% | -93.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | – | -391,213.6% | -62,927.6% | -5,447.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -368,994.2% | -62,251.7% | -5,469% |
| EPS Diluted | -0.59 | -0.58 | -0.89 | -1.23 |
| % Growth | -1.7% | 34.8% | 27.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |